Clinical Trials · NCT03044977
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
- Phase
- EARLY_Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- David Bushnell
- Enrollment
- 20
- Start date
- May 2017
- Locations
- 1 site, United States
- Primary endpoint
- glomular filtration rate (eGFR)